A Debate: Does achieving diversity in Clinical Trials actually improve health equity?

Does achieving diversity in Clinical Trials actually improve health equity? In light of the vexing challenge of enrolling enough patients in clinical trials coupled with systemic BIPOC underrepresentation within clinical trials, what are the real and imaginary tradeoffs, and do the FDA’s recent draft guidelines go far enough? Join the debate and learn from a diverse multidisciplinary panel of stakeholders–FDA, Industry, patients, patient advocates, policymakers, etc.